Analysts point out there's additional to Merck's curiosity about Idenix than its medicine portfolio-and that's the main reason Gilead's shares will be lower.
Top News & Analysis
Tags Gilead Idenix Merck's Package reports
Check Also
Connecticut has simply provided the world’ s most significant hedge fund $22M in aid
Newest sign of extended US states vying to maintain their most affluent taxpayers and avoid …